Generic Name and Formulations:
Aprepitant 40mg, 80mg, 125mg; caps.

Company:
Merck & Co., Inc.
Indications for EMEND:
In combination with other antiemetic agents to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin. Prevention of post-op nausea and vomiting.

Adult Dose for EMEND:
≥18yrs: Chemotherapy: Give with corticosteroid and 5-HT3 antagonist. Day 1 of chemotherapy cycle: 125mg 1 hour before chemotherapy; Days 2 and 3: 80mg once daily in the AM. Post-op prophylaxis: 40mg within 3hrs prior to anesthesia.

Children's Dose for EMEND:
<18yrs: not recommended.

See Also:
EMEND INJECTION

Pharmacological Class:
Substance P/neurokinin 1 receptor antagonist.

Contraindications:
Concomitant pimozide, cisapride.

Warnings/Precautions:
Not for chronic continuous use. Severe hepatic insufficiency. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:
See Contraindications. Monitor, and caution with, CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine); CYP3A4 inhibitors (eg, azole antifungals, macrolides, nefazodone, ritonavir, nelfinavir, diltiazem); and with CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each regimen); phenytoin, tolbutamide, other CYP2C9 substrates; paroxetine, oral contraceptives (use alternative or backup method during and for 1 month after last dose).

Adverse Reactions:
Asthenia, fatigue, hiccups, ALT/AST increased, headache, constipation, anorexia, GI upset, eructation, hypotension, pruritus, pyrexia. Injection: inj site pain.

How Supplied:
Caps 40mg—1; Bi-fold pack (2 x 80mg)—1; Tri-fold pack (1 x 125mg + 2 x 80mg)—1; Vial—1